S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-1.16%) $1.619
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

实时更新: Enzo Biochem Inc [ENZ]

交易所: NYSE 部门: Healthcare 工业: Diagnostics & Research
最后更新时间27 Apr 2024 @ 04:00

-1.87% $ 1.050

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...

Stats
今日成交量 114 913
平均成交量 109 219
市值 53.79M
EPS $0 ( 2024-03-19 )
下一个收益日期 ( $0 ) 2024-06-12
Last Dividend $0.0470 ( 1995-06-29 )
Next Dividend $0 ( N/A )
P/E -2.23
ATR14 $0.00300 (0.29%)
Insider Trading
Date Person Action Amount type
2024-02-23 Cannon Kara Buy 150 000 Common Stock
2024-02-21 Cannon Kara Buy 10 640 Common Stock
2024-02-21 Cannon Kara Sell 5 823 Common Stock
2024-02-23 Eckert Patricia Buy 75 000 Stock Option (to acquire shares of Common Stock)
2024-01-31 Pully Steven J Buy 79 365 Common Stock
INSIDER POWER
88.53
Last 85 transactions
Buy: 4 325 861 | Sell: 177 248

音量 相关性

長: 0.27 (neutral)
短: -0.56 (weak negative)
Signal:(51.331) Neutral

Enzo Biochem Inc 相关性

10 最正相关
YSAC0.906
TSQ0.849
HZN0.841
DTC0.828
CRD-A0.819
10 最负相关
FPEI-0.872
ASB-PE-0.868
CUBB-0.868
GL-0.855
FLR-0.852
NX-0.843
MBI-0.836
PQDI-0.832
BGSF-0.832
SPNT-PB-0.825

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Enzo Biochem Inc 相关性 - 货币/商品

The country flag 0.00
( neutral )
The country flag 0.51
( weak )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )

Enzo Biochem Inc 财务报表

Annual 2023
营收: $31.06M
毛利润: $11.57M (37.24 %)
EPS: $-1.270
FY 2023
营收: $31.06M
毛利润: $11.57M (37.24 %)
EPS: $-1.270
FY 2022
营收: $107.07M
毛利润: $41.97M (39.20 %)
EPS: $-0.460
FY 2021
营收: $117.73M
毛利润: $53.58M (45.51 %)
EPS: $0.160

Financial Reports:

No articles found.

Enzo Biochem Inc Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Enzo Biochem Inc Dividend Information - No Dividend Player

Dividend Sustainability Score: 5.02 - average (34.50%) | Divividend Growth Potential Score: 0.366 - No dividend growth expected in the near future
Information
First Dividend $0.0470 1995-06-29
Last Dividend $0.0470 1995-06-29
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.0470 --
Avg. Dividend % Per Year 0.00% --
Score 0.82 --
Div. Sustainability Score 5.02
Div.Growth Potential Score 0.366
Div. Directional Score 2.69 --
Next Divdend (Est)
(2024-04-28)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.82
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
1995 $0.0470 0.58%
1996 $0 0.00%
1997 $0 0.00%
1998 $0 0.00%
1999 $0 0.00%
2000 $0 0.00%
2001 $0 0.00%
2002 $0 0.00%
2003 $0 0.00%
2004 $0 0.00%
2005 $0 0.00%
2006 $0 0.00%
2007 $0 0.00%
2008 $0 0.00%
2009 $0 0.00%
2010 $0 0.00%
2011 $0 0.00%
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOMA Dividend Knight 2023-06-30 Quarterly 2 5.23% 8.53
KIO Dividend Royal 2023-12-14 Monthly 12 7.05% 8.50
NCZ Dividend Royal 2024-02-09 Monthly 22 7.79% 8.50
SCM Dividend King 2023-12-15 Monthly 13 7.08% 8.50
SJT Dividend Royal 2023-11-29 Monthly 39 12.52% 8.50
GOF Dividend Royal 2023-11-14 Monthly 18 8.03% 8.50
SRV Dividend Royal 2023-12-04 Monthly 18 7.53% 8.50
VGI Dividend Royal 2024-02-09 Monthly 13 7.36% 8.50
JQC Dividend Royal 2023-11-14 Monthly 22 6.56% 8.50
PHK Dividend Royal 2023-11-10 Monthly 22 6.88% 8.50

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM2.581.50010.0010.00[0 - 0.5]
returnOnAssetsTTM0.3331.20010.0010.00[0 - 0.3]
returnOnEquityTTM0.5451.5005.067.59[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM3.200.80010.008.00[1 - 3]
quickRatioTTM2.780.80010.008.00[0.8 - 2.5]
cashRatioTTM2.581.50010.0010.00[0.2 - 2]
debtRatioTTM0.0444-1.5009.26-10.00[0 - 0.6]
interestCoverageTTM33.771.00010.0010.00[3 - 30]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
freeCashFlowPerShareTTM-0.9092.00-0.455-0.909[0 - 20]
debtEquityRatioTTM0.0621-1.5009.75-10.00[0 - 2.5]
grossProfitMarginTTM-1.2031.000-10.00-10.00[0.2 - 0.8]
operatingProfitMarginTTM-0.3481.000-8.96-8.96[0.1 - 0.6]
cashFlowToDebtRatioTTM-10.101.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.1290.800-2.47-1.977[0.5 - 2]
Total Score5.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM1.6051.0009.940[1 - 100]
returnOnEquityTTM0.5452.506.827.59[0.1 - 1.5]
freeCashFlowPerShareTTM-0.9092.00-0.303-0.909[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.8792.00-0.293-0.586[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.009121.500-3.390[0.5 - 2]
operatingCashFlowSalesRatioTTM-3.471.000-10.000[0.1 - 0.5]
Total Score0.366

Enzo Biochem Inc

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。